THE BIOLOGY OF RELIEF & THE HARD QUESTIONS: An Autoethnographic Inquiry, Neurobiological Synthesis, and Legal Archive on Endocannabinoid Tone, Trauma, and Non-Suicidal Self-Injury, ( using medical cannabis as a " circuit breaker " and possible life saving intervention in adolescents diagnosed with non-suicidal self harm)
Zenodo (CERN European Organization for Nuclear Research) August 19, 2026 DOI: 10.5281/zenodo.22016062 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Interventions | Phytocannabinoid therapy high-CBD sublingual formulations |
| Topics | Cannabis |
| Key points | Argues that stress-induced central anandamide deficiency, caused by hyperactive FAAH degradation, leads to uninhibited glutamate release in the basolateral amygdala and underlies PTSD and complex trauma reactivity, proposing Clinical Endocannabinoid Deficiency as a measurable biomarker. Contends that exogenous cannabinoids can restore prefrontal connectivity and autonomic regulation, enabling participation in trauma therapies, and advocates micro-titrated high-CBD sublingual formulations as a harm-reduction alternative to unregulated concentrates and self-harm. |
Abstract
This consolidated compendium provides an interdisciplinary synthesis exploring the neurobiological mechanisms, therapeutic applications, and public health dimensions of endocannabinoid system (ECS) modulation in trauma recovery and somatic regulation. Spanning neurobiology, clinical traumatology, and health policy, the work examines how targeted phytocannabinoid therapy serves as an essential somatic bridge for individuals navigating severe emotional dysregulation, autonomic hyperarousal, and non-suicidal self-injury (NSSI). 1. Neurobiological Foundations & CECD Trait Markers: Stress-induced impairments in central anandamide (AEA) signaling, driven by hyperactive fatty acid amide hydrolase (FAAH) degradation, lead to uninhibited glutamate release within the basolateral amygdala (BLA). This neurochemical collapse underlies the heightened physiological reactivity observed in post-traumatic stress disorder (PTSD) and complex developmental trauma, establishing Clinical Endocannabinoid Deficiency (CECD) as a measurable biomarker. 2. Somatic Regulation & Therapeutic Integration: Exogenous cannabinoid administration acts as a presynaptic circuit breaker, reducing sympathetic overdrive to lower acute distress. By restoring prefrontal cortex (mPFC) executive connectivity, targeted neuromodulation anchors the patient within the Window of Tolerance, enabling effective participation in evidence-based modalities such as Somatic Experiencing (SE), Dialectical Behavior Therapy (DBT), and EMDR. 3. Harm Reduction, Protocols, & Public Research: Evaluating high-potency unregulated concentrates against balanced clinical formulations highlights the necessity of pragmatic harm-reduction protocols. Implementing micro-titrated, high-CBD sublingual formulations offers a non-lethal, tissue-preserving alternative to pharmaceutical overdose and physical self-harm. Systematic auditing of federally funded grant portfolios (NIH/NIDA/NIMH) confirms strong basic-science backing for CB1 receptor targets.